Charles River Laboratories International, Inc. CRL
345.80 USD -7.54 (-2.13%)
At closeNov 10, 2026, 4:52 PM EST
345.80 0.00 0.00%
After hours · Nov 10, 4:52 PM ET
342.39 Day range 352.27
146.20 52-week range 379.63
- YTD
- +73.35%
- 1 year
- +104.65%
News
benzinga.com Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says Charles River Laboratories will buy Frontage's bioanalysis unit for $470 million in cash to expand its clinical drug testing scale.
prnewswire.com Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business HANGZHOU, China, Nov. 10, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK, hereinafter referred to as "Tigermed"), a leading global provider of…
zacks.com Here's Why Charles River Laboratories (CRL) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and Prospects Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
benzinga.com Charles River Laboratories To Acquire Frontage Holdings Corporation’s Bioanalysis And DMPK Operations In Pennsylvania For ~$470M In Cash Plus Additional Payments Of Up To $75M The transaction is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals, and other customary closing conditions. Frontage’s laboratory testing…
businesswire.com Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses.
benzinga.com UBS Maintains Buy on Charles River, Raises Price Target to $387 UBS analyst Kevin Caliendo maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $357 to $387.
benzinga.com RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352 RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $322 to $352.
benzinga.com Barclays Maintains Overweight on Charles River, Raises Price Target to $375 Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $330 to $375.
benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $330 to $400.
marketbeat.com Charles River Laboratories International Q3 Earnings Call Highlights Charles River Laboratories International NYSE: CRL raised its 2026 revenue and earnings outlook after third-quarter organic revenue growth accelerated to 4.7%, supported by demand for safety…
defenseworld.net Boston Trust Walden Corp Sells 37,537 Shares of Charles River Laboratories International, Inc. $CRL Boston Trust Walden Corp reduced its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 13.0% during the undefined quarter, according to its most recent 13F filing with the…
seekingalpha.com Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript
zacks.com Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises CRL beats Q3 earnings and revenue estimates as organic growth and margin expansion drive results, prompting the company to raise its 2026 outlook.
zacks.com Charles River (CRL) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with…
benzinga.com Charles River Q3 2026 Earnings Call Transcript Charles River (NYSE:CRL) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
zacks.com Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates Charles River Laboratories (CRL) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.43 per share a year ago.- benzinga.com Charles River Widens FY2026 Adj EPS Guidance from $11.45 to $11.35-$11.55 vs $11.38 Est; Raises FY2026 Sales Guidance from $3.915B to $3.940B-$3.960B vs $3.916B Est Charles River (NYSE:CRL) widens FY2026 Adj EPS guidance from $11.45 to $11.35-$11.55 vs $11.38 analyst estimate. Raises FY2026 sales outlook from $3.915 billion to $3.940 billion-$3.960 billion vs…
businesswire.com Charles River Laboratories Announces Third-Quarter 2026 Results WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Third-Quarter 2026 Results.
zacks.com Charles River's Q3 Earnings on Deck: What's in Store for the Stock? CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
zacks.com Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy? Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
seekingalpha.com Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds…
benzinga.com Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the…
businesswire.com Charles River Leverages Virtual Control Groups in GLP Studies WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.
defenseworld.net Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) Director James Foster sold 24,042 shares of the company's stock in a transaction dated Thursday, October 22nd. The shares…
defenseworld.net 8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC Evergreen Capital Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) in the third quarter, according to its most recent disclosure with the Securities…
seekingalpha.com Ariel Fund Q3 2026 Leaders And Laggards ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology…- benzinga.com Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
businesswire.com Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of…
benzinga.com $1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market…
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
defenseworld.net Charles River Laboratories International (NYSE:CRL) Share Price Crosses Above 200 Day Moving Average – Should You Sell? Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred…
benzinga.com Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market…
benzinga.com Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340 Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.- benzinga.com Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the…
- benzinga.com Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the…
- benzinga.com Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market…
- benzinga.com Jefferies Maintains Buy on Charles River, Raises Price Target to $340 Jefferies analyst David Windley maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.
- benzinga.com Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320 Deutsche Bank analyst Justin Bowers maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.
benzinga.com TD Cowen Maintains Buy on Charles River, Raises Price Target to $325 TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.- benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.
benzinga.com RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322 RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.- benzinga.com Barclays Maintains Overweight on Charles River, Raises Price Target to $330 Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.
- benzinga.com Mizuho Maintains Neutral on Charles River, Raises Price Target to $295 Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.
benzinga.com Baird Maintains Outperform on Charles River, Raises Price Target to $334 Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.
benzinga.com S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
benzinga.com Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.- benzinga.com Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7% Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term…
- benzinga.com Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.57% on an annualized basis producing an average annual return of 15.86%. Currently, Charles River has a market…
- benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.